Cash/Burn From SEC Filing For Period: 

Q1' 20

CHRS

Coherus BioSciences Inc.

Cash

$193.3M

Burn Rate

-$35.6M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

UDENYCA® (pegfilgrastim-cbqv) Biosimilar

Oncology

Quarterly Sales (Approved)

August 6, 2020

Innovent’s Avastin® Biosimilar (bevacizumab)

Non-small-cell lung carcinoma (NSCLC)

Phase 3 (BLA Filing)

Late 2020 / Early 2021

Humira® (adalimumab) Biosimilar - CHS-1420

Anti-TNF (tumor necrosis factor)

Phase 3 (BLA Filing)

H2 2020

Lucentis® (ranibizumab) Biosimilar

Ophthalmology

Phase 3 (BLA Filing)

H2 2020

CHS-131

Nonalcoholic steatohepatitis (NASH)

Phase 2

TBD

Enbrel® (etanercept) Biosimilar

ANTI-TNF (tumor necrosis factor)

Phase 2 (BLA Filing)

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon